Vaso Corporation Announces Fifth Extension of Sales Representation Agreement with GE HealthCare
MWN-AI** Summary
Vaso Corporation (OTCQX: VASO) announced a significant milestone in its partnership with GE HealthCare (NASDAQ: GEHC) by extending their sales representation agreement for the fifth time, now set to continue through December 31, 2030. This extension reaffirms their collaborative efforts that began in May 2010 and highlights their commitment to enhancing diagnostic imaging and ultrasound solutions in the U.S. healthcare market.
Under this renewed agreement, Vaso’s subsidiary, VasoHealthcare, will continue to represent GE HealthCare's wide array of diagnostic imaging and ultrasound products, including advanced technologies such as CT, MR, molecular imaging, X-ray, mammography, and interventional guided solutions. This strategic partnership is aimed at not only sustaining sales performance but also integrating VasoHealthcare's expertise with GE HealthCare’s innovative technologies to improve patient outcomes and adapt to the evolving needs of healthcare providers.
Leaders from both companies emphasized the importance of this partnership. Catherine Estrampes, President & CEO of GE Healthcare U.S. and Canada, remarked on the strong foundation of trust and collaboration formed over the years, which ultimately benefits healthcare providers nationwide. Jane Moen, President of VasoHealthcare and COO of Vaso Corporation, highlighted the successful expansion into ultrasound products alongside the existing diagnostic imaging equipment. Dr. Jun Ma, President and CEO of Vaso Corporation, expressed gratitude towards the VasoHealthcare team for their dedication and professionalism, recognizing that their efforts contributed significantly to this enduring relationship.
Vaso Corporation, headquartered in Plainview, New York, operates through three primary subsidiaries, with VasoHealthcare serving as a vital link in the distribution of GE HealthCare products. The continuity of this partnership is poised to support healthcare providers, particularly in rural and underserved markets, delivering innovations essential for superior patient care.
MWN-AI** Analysis
Vaso Corporation’s recent announcement regarding the extension of its sales representation agreement with GE HealthCare through December 31, 2030, marks a significant milestone for the company and its stakeholders. For investors, this fifth extension underscores the long-term stability of Vaso's operations and its integral role in the healthcare supply chain.
The partnership, which began in May 2010, emphasizes VasoHealthcare’s ongoing commitment to representing GE HealthCare’s extensive portfolio of diagnostic imaging and ultrasound products. This continuity is crucial given the industry's reliance on consistent access to cutting-edge technology, particularly as healthcare providers navigate evolving clinical demands in the aftermath of the pandemic.
From a market perspective, this announcement could bolster investor confidence in Vaso Corporation. The sustained relationship not only highlights Vaso's expertise in the medical sales field but also positions the company as a reliable player within the healthcare sector. This is particularly pertinent as Vaso expands its service offerings, potentially further solidifying its market presence and driving revenue growth.
Moreover, the commitment to innovation and patient care through advanced medical technologies aligns well with current healthcare trends focused on improving patient outcomes. As such, Vaso could see increased demand for its services, particularly in underserved markets, thereby providing a potentially lucrative avenue for revenue expansion.
Investors should consider these developments when evaluating Vaso Corporation's stock, especially given the company's diversified business model that includes technology and medical device manufacturing. However, caution is advised as market risks remain, particularly due to economic fluctuations and competitive pressures in the healthcare sector. Overall, Vaso Corporation presents a potentially promising investment opportunity, though careful monitoring of industry dynamics and company performance is essential.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Vaso Corporation
137 Commercial Street
Plainview, New York 11803
Tel: (516) 997-4600 Fax: (516) 997-2299
Investor Contact:
Jonathan Newton
Investor Relations
Phone: 516-997-4600
Email: jnewton@vasocorporation.com
PLAINVIEW, N.Y., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation (OTCQX: VASO) announced today that its wholly owned subsidiary, Vaso Diagnostics, Inc. d/b/a VasoHealthcare, has signed an amendment to the sales representation agreement with GE HealthCare (NASDAQ: GEHC) to extend the term of the agreement through December 31, 2030. This is the fifth time the parties have agreed to extend the term of the agreement and establishes a significant milestone in this longstanding collaboration, which began in May 2010. By virtue of the latest extension, the relationship will ultimately span over 20 years, reinforcing the shared commitment to advancing diagnostic imaging and ultrasound solutions across the United States.
Under the terms of this latest amendment, VasoHealthcare will continue to represent GE HealthCare’s portfolio of diagnostic imaging and ultrasound products and services, including CT, MR, molecular imaging, X-ray, mammography, and interventional guided solutions systems, as well as associated service and financial offerings. The amendment builds upon the success of the long-term relationship, ensuring continuity in sales representation and alignment with GE HealthCare’s commercial strategy. The collaboration has consistently delivered strong results, leveraging VasoHealthcare’s expertise and GE HealthCare’s technologies to help improve patient outcomes and support healthcare providers in meeting evolving clinical demands. This extension underscores both organizations’ dedication to delivering cutting-edge technology and exceptional customer support to healthcare providers nationwide.
“This extension reflects the strength and longevity of our partnership with VasoHealthcare, built on a shared commitment to advancing patient care in the U.S. and, ultimately, helping to build a healthier future,” said Catherine Estrampes, President & CEO, U.S. and Canada, GE Healthcare.
“This milestone reflects a partnership built on trust, execution, and shared purpose. Extending the agreement between GE HealthCare and VasoHealthcare gives customers continuity and confidence. Our team – serving community hospitals, outpatient imaging centers, and specialty practices, including rural and underserved markets – will continue bringing GE HealthCare innovation to the point of care with the service, expertise, and urgency that customers expect,” shared Ms. Jane Moen, President, VasoHealthcare and COO, Vaso Corporation.
“The success of the representation program for GE HealthCare’s diagnostic imaging equipment has also expanded our partnership to include ultrasound products. I would like to thank all employees of VasoHealthcare and wish you continued success. We would not be able to achieve any of these without your dedication and professionalism,” added Dr. Jun Ma, President and CEO of Vaso Corporation.
About Vaso
Vaso Corporation (OTCQX: VASO), headquartered in Plainview, New York, is a diversified organization with three core businesses operating as wholly-owned subsidiaries: VasoHealthcare, the professional sales service arm for GE HealthCare's diagnostic imaging and ultrasound products; VasoTechnology, an information technology and managed connectivity leader serving customers in healthcare provision and other sectors; and VasoMedical, the designer and manufacturer of proprietary medical devices including Biox series devices and the developer and operator of the ARCS cloud-based SaaS platform.
For additional information, please visit www.vasocorporation.com or contact us at info@vasocorporation.
Forward Looking Statements. Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “optimistic”, “plans”, “potential”, “looking forward”, and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions, including the possibility of a downturn in the US economy and the continued impact of the COVID-19 pandemic; failure to achieve any portion of the earnout; the effect of the dramatic changes taking place in IT and healthcare; continuation of the GEHC agreement; the impact of competitive technology and products and their pricing; medical insurance reimbursement policies; manufacturing or supplier problems; unforeseen difficulties and delays in product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
# # #
FAQ**
How does the extended agreement with GE HealthCare impact Vaso Corp VASO's revenue projections and overall growth strategy through 2030?
2. What are the key performance metrics Vaso Corp VASO will focus on to evaluate the success of its partnership with GE HealthCare over the next few years?
3. In what ways does Vaso Corp VASO plan to leverage its diverse business segments to enhance its competitive position in the healthcare market?
4. How does Vaso Corp VASO intend to address potential risks associated with the evolving healthcare landscape as mentioned in its forward-looking statements?
**MWN-AI FAQ is based on asking OpenAI questions about Vaso Corp (OTC: VASO).
NASDAQ: VASO
VASO Trading
1.16% G/L:
$0.1661 Last:
1,830 Volume:
$0.1642 Open:
